Publications

Read ASGCT's 2023 Q4 Landscape Analysis Field Report

Read & download the full report | January 12, 2024

In Q4, FDA approved U.S.-first gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease.

Publications

Read Full Story

Read ASGCT's 2023 Q2 Landscape Analysis Field Report

July 13, 2023

The second quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Publications

Read Full Story

Read ASGCT's 2023 Q1 Landscape Analysis Field Report

April 18, 2023

The first quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Publications

Read Full Story

Read ASGCT's 2022 Q4 Landscape Analysis Field Report

January 20, 2023

The Gene, Cell, & RNA Therapy Landscape report from ASGCT and Citeline (formerly Informa Pharma Intelligence) is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Publications

Read Full Story